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Background: Antiretroviral therapy (ART) reduces the risk of
Tuberculosis (TB) among people living with HIV (PLWH). With
ART scale-up in sub-Saharan Africa over the past decade,
incidence of TB among PLWH engaged in HIV care is predicted
to decline.
Methods: We conducted a retrospective analysis of routine clinical
data from 168,330 PLWH receiving care at 35 facilities in Kenya,
Tanzania, and Uganda during 2003–2012, participating in the East
African region of the International Epidemiologic Databases to
Evaluate AIDS. Temporal trends in facility-based annual TB
incidence rates (per 100,000 person years) among PLWH and
country-speciﬁc standardized TB incidence ratios using annual
population-level TB incidence data from the World Health Organi-
zation were computed between 2007 and 2012. We examined
patient-level and facility-level factors associated with incident TB
using multivariable Cox models.
Results: Overall, TB incidence rates among PLWH in care declined
5-fold between 2007 and 2012 from 5960 to 985 per 100,000 person
years [P = 0.0003] (Kenya: 7552 to 1115 [P = 0.0007]; Tanzania:
7153 to 635 [P = 0.0025]; Uganda: 3204 to 242 [P = 0.018]).
Standardized TB incidence ratios signiﬁcantly decreased in the 3
countries, indicating a narrowing gap between incidence rates among
PLWH and the general population. We observed lower hazards of
incident TB among PLWH on ART and/or isoniazid preventive
therapy and receiving care in facilities offering TB treatment onsite.
Conclusions: Annual TB incidence rates among PLWH signiﬁ-
cantly declined during ART scale-up but remained higher than the
general population. Increasing access to ART and isoniazid pre-
ventive therapy and co-location of HIV and TB treatment may
further reduce TB incidence among PLWH.
Key Words: TB incidence rates, tuberculosis, TB/HIV, HIV, ART,
sub-Saharan Africa
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INTRODUCTION
Tuberculosis (TB) is the most common opportunistic
infection among people living with HIV (PLWH) and the
leading cause of death in PLWH globally.1 Between 1990 and
2000, HIV-associated TB drove increasing TB incidence
trends in sub-Saharan Africa,2 although rates stabilized or
declined elsewhere.3 In 2000, Jones et al4 found that
antiretroviral therapy (ART) was highly effective in reducing
the risk of TB disease in a US-based cohort. Subsequently, 8
PLWH cohorts from diverse settings, including sub-Saharan
Africa,4–13 reported an average decline of 67% (95% Conﬁ-
dence Interval (CI): 61% to 73%) in the risk of TB associated
with ART over an average 2-year follow–up.14,15 Meanwhile,
ART coverage among all PLWH increased rapidly in sub-
Saharan Africa since 2005 from single digits to 39% in
2014.16 Mathematical models have since then shown declin-
ing HIV-associated TB during the past decade in sub-Saharan
Africa.17,18 These models included expanding ART coverage
along with TB notiﬁcation rates and baseline CD4 counts of
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PLWH as parameters. A few empirical studies have found
declining case notiﬁcation rates coinciding with ART scale-
up.19,20 In addition, a recent study in Kenya found that during
2007–2012, estimated TB incidence declined by 28%–44%
among PLWH—including those who are engaged and not
engaged in HIV care—concurrent with an increase in ART
uptake.21 To date, no study has examined temporal trends in
facility-based annual TB incidence rates among PLWH
engaged in HIV care over a period of rapid ART scale-up
in sub-Saharan Africa. Furthermore, although a number of
patient factors associated with incident TB disease among
PLWH have been described,4,6–8,22–26 there are little data on
the potential inﬂuence of facility-level factors, such as type
and location of the facility, availability, and co-location of
integrated TB/HIV services.
We used clinical data collected from 2003–2012 within
the East African region of the International epidemiologic
Databases to Evaluate AIDS (IeDEA) to determine temporal
trends in facility-based annual TB incidence rates among
PLWH in HIV care at predominantly public health facilities
serving urban and semiurban population and to assess patient-
level and facility-level factors associated with incident TB.
METHODS
Study Design
This is a retrospective study using data collected
during routine clinical encounters from the East Africa
IeDEA Cohort. The study period varied according to the
country: January 2003 to December 2012 in Kenya and
Uganda, and January 2006 to December 2012 in Tanzania.
This study was approved by Moi Teaching and Referral
Hospital/Moi University Institutional Research and Ethics
Committee, Mbarara University of Science and Technology
Institutional Review Committee, Uganda National Council
for Science and Technology, St. Raphael of St. Francis
Hospital Institutional Review Ethics Committee, Makerere
University School Medicine Research & Ethics Committee,
The United Republic of Tanzania Medical Research Coor-
dinating Committee of the National Institute for Medical
Research, Kenya Medical Research Institute/National
Ethics Review Committee. Written consent was waived
by the IRB because of the transmission of only deidentiﬁed
data disseminated from the Regional Data Coordinating
Center (RDC).
Study Setting
Eight programs representing 35 health facilities con-
tributed data for analysis.27
Study Population
PLWH who were $18 years of age, ART-naïve, and
TB-disease–free at HIV care enrollment were included.
PLWH with TB at enrollment or who initiated anti-TB
treatment within 60 days of enrollment (25,300 patients)
were excluded as possible prevalent cases.
Data Collection and Management
Data were collected using clinic-speciﬁc standard
data collection forms and entered into patient-level data-
bases locally. Prospective data quality controls to optimize
accuracy and reduce missing data were incorporated into all
data collection systems using methods for reconciliation of
errors and retrieval of missing information from clinicians
and primary records. At every site, periodic audits were
conducted by the East African IeDEA RDC (Indiana
University and Moi University) to identify errors, review
data collection or entry procedures and investigate
missing data. Data from all sites were harmonized at the
RDC. Facility-level data were collected using an IeDEA
facility survey.28
Analysis
The outcome of interest was the ﬁrst incident TB
diagnosis, deﬁned as ﬁrst documentation of anti-TB medi-
cations within the patient record at least 2 months after
enrollment into HIV care. Subsequent TB episodes were not
included. TB diagnosis and subsequent initiation of treatment
were largely based on clinical evaluation and smear micros-
copy during the period of this analysis.
Annual crude TB incidence rates [per 100,000 person
years (PYs)] were estimated stratiﬁed by ART status (pre-
ART or on ART), and age group (18–19, 20–29, 30–39,
40–49, 50+ years of age). We restricted the period of the
trend analysis to 2007–2012 because estimates for the years
before 2007 were unstable because of limited person time
on follow-up. Time-updated ART status was used to
account for different levels of risk during the pre-ART
and ART phase. The annual crude TB incidence rates were
divided by annual TB incidence rates (per 100,000
population per year) for the general population estimated
by the World Health Organization (WHO), to derive
country-speciﬁc standardized TB incidence ratios (SIRs)29
for PLWH enrolled in HIV care at study sites. SIRs
represent the relative likelihood that HIV patients in care
would develop TB disease, as compared to the general
population in the same country in a given year. To assess
temporal trends in crude incidence rates and SIRs, linear
regression was used.30
We ﬁtted adjusted Cox proportional-hazard models to
138,394 (82% of 168,330) PLWH with available data on all
patient and facility variables, including imputed CD4 cell
count and WHO stage, to examine the temporal trend in TB
incidence after adjusting for patient-level and facility-level
factors. Patient-level factors considered in adjusted analyses
were age at enrollment, sex, enrollment year, WHO stage,
CD4 cell count at enrollment, time-dependent ART use,
history of TB disease before enrollment and use of isoniazid
preventive therapy (IPT) at any time during HIV care.
Facility-level factors included type of population served
(rural, semi-urban, or urban), facility type (public, private,
or other), availability of anti-TB treatment onsite, availability
of routine TB screening based on a symptom checklist, and
availability of IPT at the HIV clinic. We also assessed criteria
for Cotrimoxazole preventive therapy (CPT) eligibility
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TABLE 1. Clinical Characteristics of Patients Enrolling in HIV Care in 35 Facilities Participating in IeDEA-East Africa, 2003–2012
Kenya Tanzania Uganda Overall
Number of patients 111,556 13,392 43,382 168,330
Age at enrolment
Median, IQR 34.5 (28.2–42.2) 35.3 (29.5–42.5) 33.3 (38.0–40.1) 34.3 (28.2–41.5)
Missing 355 2 22 379
Sex
Female 77,953 (69.9) 9635 (71.9) 28,303 (65.2) 115,891 (68.6)
Male 33,603 (30.1) 3757 (28.1) 15,079 (34.8) 52,439 (31.2)
Enrolment year
2003 1256 (1.1) NA 2693 (6.2) 3949 (2.3)
2004 4574 (4.1) NA 5322 (12.3) 9896 (5.9)
2005 9488 (8.5) NA 8038 (18.5) 17,526 (10.4)
2006 14,297 (12.8) 1949 (14.6) 5795 (13.4) 22,041 (13.1)
2007 16,358 (14.7) 2696 (20.1) 3981 (9.2) 23,035 (13.7)
2008 14,386 (12.9) 2810 (21.0) 4535 (10.5) 21,731 (12.9)
2009 16,366 (14.7) 1864 (13.9) 4195 (9.7) 22,425 (13.3)
2010 15,233 (13.7) 1706 (12.7) 5106 (11.8) 22,045 (13.1)
2011 13,465 (12.1) 1482 (11.1) 2918 (6.7) 17,865 (10.6)
2012 6133 (5.5) 885 (6.6) 799 (1.8) 7817 (4.6)
Follow-up time (mo)
Median, IQR 42.1 (20.3–67.2) 44.6 (21.9–59.9) 50 (19.9–71.3) 44 (20.3–67.9)
Pre-ART 31.2 (12.0–56.8) 29.3 (11.1–49.9) 37.2 (12.0–62.4) 32.6 (12.0–58.6)
ART 46.7 (25.0–69.6) 48.8 (29.5–62.1) 56 (27.2–74.5) 49 (25.7–70.3)
CD4+ cells/mL at enrollment
Median, IQR 280 (137–457) 261 (115–410) 297 (138–475) 283 (135–457)
0–99 20,437 (18.3) 2880 (21.5) 7541 (17.4) 30,858 (18.3)
100–199 21,068 (18.9) 2652 (19.8) 7269 (16.8) 30,989 (18.4)
200–350 25,758 (23.1) 2859 (21.4) 10,051 (23.2) 38,668 (23.0)
351–500 22,884 (20.5) 3186 (23.8) 9800 (22.6) 35,870 (21.3)
.500 21,297 (19.1) 1809 (13.5) 8716 (20.1) 31,822 (18.9)
Missing 112 6 5 123
WHO stage at enrollment
Stage 1 54,836 (49.2) 3869 (28.9) 11,511 (26.5) 70,216 (41.7)
Stage 2 23,925 (21.5) 4854 (36.2) 16,342 (37.7) 45,121 (26.8)
Stage 3 28,523 (25.6) 3340 (24.9) 10,886 (25.1) 42,749 (25.4)
Stage 4 4192 (3.8) 1329 (9.9) 4642 (10.7) 10,163 (6.0)
Missing 80 0 1 81
Use of ART
Yes 66,612 (59.7) 6450 (48.2) 19,390 (44.7) 92,452 (54.9)
No 44,944 (40.3) 6942 (51.8) 23,992 (55.3) 75,878 (45.1)
2003 419 (33.4) — 436 (16.2) 855 (21.7)
2004 2363 (42.6) — 1403 (20.1) 3766 (30.1)
2005 6976 (50.0) — 4432 (35.3) 11,408 (43.0)
2006 12,790 (51.1) 786 (40.3) 5468 (39.0) 19,044 (46.4)
2007 17,943 (50.3) 1767 (46.5) 7084 (49.7) 26,794 (49.9)
2008 22,629 (53.6) 2511 (49.2) 8616 (54.3) 33,756 (53.4)
2009 29,710 (59.6) 2848 (57.3) 9845 (58.2) 42,403 (59.1)
2010 36,326 (65.6) 3082 (62.8) 11,250 (59.5) 50,658 (63.9)
2011 41,759 (72.0) 3106 (64.6) 12,117 (67.0) 56,982 (70.4)
2012 38,979 (78.1) 3102 (72.6) 5740 (75.4) 47,821 (77.4)
Use of isoniazid preventive therapy
Yes 21,436 (19.2) 52 (0.4) 216 (0.5) 21,704 (12.9)
No 90,120 (80.8) 12,740 (99.6) 20,278 (99.5) 123,138 (87.1)
Missing 0 600 22,888 23,488
History of TB
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against 2006 WHO guidelines31 (eligibility criteria of CD4
cell counts either ,350 or ,500 cells per microlitter as fully
consistent; CD4 counts ,200 cells per microlitter or WHO
stage III or IV as partially consistent).
Age and year of enrollment were treated as continu-
ous variables. All other factors were treated as categorical
variables. Records were censored at the date of the event or
the last clinic visit for individuals identiﬁed as dead, lost to
follow-up (LTFU), or transferred out. LTFU was deﬁned as
no visits for 6 months (for patients on ART) and 12 months
(for pre-ART patients) without documentation of death or
transfer. Patient-level and facility-level factors that were
signiﬁcant at the a = 0.20 level in unadjusted analyses were
included into the adjusted model. In the adjusted model,
statistical signiﬁcance was determined at the a = 0.05 level.
History of TB disease before enrollment was not available
for the Tanzanian clinics and thus excluded from the
adjusted model. We used robust standard errors to account
for within-individual correlation resulting from treating
ART as a time-dependent variable.
To examine the robustness of ﬁndings, we compared
results including PLWH with imputed values for CD4 cell
count and WHO stage at enrollment with results excluding
them. Additionally, we ran country-speciﬁc models to
examine whether observed associations in the multicountry
model was driven by a single country. Statistical analyses
were conducted in Stata version 10.0 (College station, TX).
Multiple imputation techniques were used to impute
CD4 cell count for 23% and WHO stage for 12% of patients
with missing data at enrollment based on a country-speciﬁc
algorithm adapted from Yiannoutsos et al32 using WHO
stage at enrollment if available to impute CD4 cell count
and CD4 cell count if available to impute WHO stage, as
well as age group, sex, and time from enrollment to ART
start for ART patients for both measures.
RESULTS
Patient and Clinic Characteristics
Overall 168,330 adult PLWH enrolled in HIV care
between 2003 and 2012 with a median follow-up time of 44
months [interquartile range (IQR): 20.3–67.9] (Table 1). Most
patients were women (69%) with a median age of 34 (IQR:
28–42). Median CD4 cell count at enrollment was 283 cells
per microliter (IQR: 135–457 cells per microliter) with little
variability across countries. Approximately, one-third of
patients were enrolled with a WHO stage of III/IV disease.
The proportion of patients with documented history of TB at
enrollment ranged from 0.3% in Uganda to 5% in Kenya. IPT
use was signiﬁcantly higher in Kenya (19%) when compared
with that in Tanzania and Uganda (,1%).
The proportion of PLWH initiating ART in any given
year increased from 22% in 2003 to 77% in 2012. In Kenya,
60% of enrolled patients had initiated ART during the
observation period compared to 48% in Tanzania and 45%
in Uganda. 57% of patients were LTFU while in pre-ART
care and 26% after ART initiation and 6% were known to
have died.
TABLE 1. (Continued ) Clinical Characteristics of Patients Enrolling in HIV Care in 35 Facilities Participating in IeDEA-East Africa,
2003–2012
Kenya Tanzania Uganda Overall
Yes 5308 (4.8) NA 118 (0.3) 5426 (3.2)
No 106,248 (95.2) NA 6281 (99.7) 112,529 (96.8)
Missing 0 13,392 36,983 50,375
Data is presented as n(%).
TABLE 2. Clinic Characteristics of IeDEA-East Africa Health
Facilities, 2009
Kenya Tanzania Uganda Overall
Number of health facilities 27 3 5 35
Population served by facility
Urban only 8 (30) 2 (67) 4 (80) 14 (40)
Rural only 5 (19) 0 (0) 0 (0) 5 (14)
Semiurban only 10 (37) 0 (0) 0 (0) 10 (29)
Urban and semiurban 4 (15) 1 (33) 0 (0) 5 (14)
Rural and semiurban 0 (0) 0 (0) 1 (20) 1 (3)
Facility type
Public 24 (89) 3 (100) 4 (80) 31 (89)
Private/other 3 (11) 0 (0) 1 (20) 4 (11)
Availability of TB treatment
within facility
Yes 18 (67) 1 (33) 3 (60) 22 (63)
No 9 (33) 2 (67) 2 (40) 13 (37)
Routine TB screening at the HIV
clinic
Yes 25 (93) 2 (67) 5 (100) 32 (91)
No 2 (7) 1 (33) 0 (0) 3 (9)
Availability of isoniazid
preventive therapy at the HIV
clinic
Yes 19 (70) 0 (0) 1 (20) 20 (57)
No 8 (30) 3 (100) 4 (80) 15 (43)
Consistency with WHO guidelines
for Cotrimoxazole among
PLWH
Fully consistent 9 (33) 2 (67) 3 (60) 14 (40)
Partially consistent 18 (67) 1 (33) 2 (40) 21 (60)
Data is presented as n(%).
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Patients received care in 35 health facilities (27 in
Kenya, 3 in Tanzania, and 5 in Uganda). Most facilities
served urban and semiurban populations (Table 2). Eighty
nine percentage were public-sector facilities, 63% offered
anti-TB treatment onsite, and 91% reported routine
symptom-based TB screening. Onsite IPT availability
was variable across countries, Kenya reported availability
in 70%, Uganda in 20%, and Tanzania in no facilities.
Consistency with WHO CPT guidelines was reported at
33%, 67%, and 60% of the facilities in Kenya, Tanzania,
and Uganda, respectively.
Overall and Temporal Trends in TB Incidence
Between 2003 and 2012, 12,967 incident cases of TB
were identiﬁed, 5471 during pre-ART and 7496 during
ART period (Table 3).The overall 10-year crude TB
incidence rate was 3986 per 100,000 PYs. Higher rates
were reported in PLWH from Kenyan and Ugandan sites
(4056 and 4138 per 100,000 PYs, respectively) compared to
Tanzania (2321 per 100,000 PYs). In Uganda, TB incidence
rates were highest among patients aged 18–19 years old and
steadily declined with age. Across the 3 countries, the
lowest TB incidence rates were found among the 50+
age group.
Crude TB incidence rates declined from 5960 to 981
per 100,000 PYs between 2007 and 2012 (coef.=21889; P =
0.0003) (Table 3). The reduction in incidence was seen in all
3 countries [Kenya: from 7552 to 1115 (coef.=22067; P =
0.0007); Tanzania: 7153 to 635 (coef.=21253; P = 0.0025);
Uganda: 3204 to 242 (coef.=22017; P = 0.018)] (Fig. 1,
Table 3). The declining trends were evident across pre-ART
(coef.=21487; P = 0.0002) and ART patients (coef.=23290;
P = 0.0004) and across all age groups, except the 18–19 age
group for Uganda (Fig. 2).
TB Incidence Among PLWH Compared to the
General Population
SIRs showed similar trends from 2007 to 2012 [Kenya:
21.8 to 4.1 (P = 0.0019); Tanzania: 53.4 to 3.1 (P = 0.0022);
and Uganda: 12.2 to 1.4 (P = 0.0404)], indicating substantial
decreases in TB incidence among PLWH engaged in HIV care
relative to the general population (Table 3). Despite this decrease
over the study period, enrolled PLWH continued to have a 1.4–
4.1 times higher TB incidence than the general population.
Adjusted Analysis of Temporal Trends in
TB Incidence
In the adjusted analysis, more recent year was associated
with a lower hazard of TB disease. Other lower hazards of TB
were increasing age, enrollment CD4 cell count between 100
and 199 cells per microlitter and . 350 cells per microliter
(vs.,100 cells/mL), use of ART and IPT and receiving care at
facilities with both HIV and anti-TB treatment available
onsite. Factors associated with higher hazards of TB included
male sex and WHO stage II, III and IV (vs. WHO stage I) at
enrollment; receiving care in public health facilities (vs.
private facilities), facilities not exclusively serving an urban
population (vs. urban population only), and facilities with
routine symptom-based TB screening (Table 4).
TABLE 3. Crude TB Incidence Rates and Standardized
Incidence Ratios Among HIV Positive Individuals Enrolling in
HIV Care in IeDEA-East Africa Health Facilities, January 2003–
December 2012
Kenya Tanzania Uganda Overall
Number of patients 111,556 13,392 43,382 168,330
Number of incident
TB cases
All 9149 396 3422 12,967
Pre-ART 3430 136 1905 5471
ART 5719 260 1517 7496
Person months
of follow-up
All 225,554 17,064 82,690 325,308
Pre-ART 84,218 5957 37,248 127,424
ART 141,335 11,107 45,442 197,883
TB incidence
(per 100,000 PYs)
All 4056 2321 4138 3986
ART status
Pre-ART 4073 2283 5114 4294
ART 4046 2341 3338 3788
Age group
18–19 4089 0 5658 4285
20–29 4167 2124 4514 4166
30–39 4178 2193 4372 4118
40–49 3865 2396 3574 3703
50+ 3824 2010 3213 3585
Calendar year*
2003 46,568 — 27,332 36,666
2004 20,686 — 7721 12,601
2005 13,708 — 25,820 19,787
2006 9263 8711 10,775 9888
2007 7552 7153 3204 5960
2008 5242 4878 3041 4604
2009 5124 2749 3234 4475
2010 3758 2090 2407 3332
2011 2950 1348 1208 2367
2012 1115 635 242 981
Standardized TB incidence
ratio*†
2003 133.4 — 78.1 —
2004 57.9 — 23.7 —
2005 38.2 — 84.9 —
2006 26.1 43.6 38.1 —
2007 21.8 53.4 12.2 —
2008 15.8 28.9 12.5 —
2009 16.4 17.8 14.3 —
2010 12.6 13.2 11.5 —
2011 10.2 8.4 5.3 —
2012 4.1 3.1 1.4 —
*Italicized rates are not included in calculations of trend statistics.
†Standardized TB incidence ratios = Rate ratio of TB incidence of PLWH in care
over TB incidence of general population.
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In sensitivity analyses excluding observations with
imputed values for CD4 cell count and WHO stage, we
found higher TB incidence among those with missing CD4
cell count and/or WHO stage values. Those with missing
values had an overall incidence rate of 4477 per 100,000 PYs
compared with those without missing values that had an
overall incidence rate of 3868 per 100,000 PYs. This is likely
because they were less likely to be on ART (35.9% vs.
62.5%) and on IPT (7.9% vs. 17.7%). Model results
excluding imputed values for CD4 cell count and the WHO
stage, however, yielded consistent results with those using
imputed data with minor variation in point estimates and P-
values, which indicated no signiﬁcant differences in factors
associated with incident TB between the 2 groups. Addition-
ally, we ran country-speciﬁc models and found that more
recent enrollment years were associated with lower hazard
ratio for TB in all models. Although we found broad
consistency in the direction of association with patient-level
and facility-level factors with incident TB, we found impor-
tant differences in a few variables. At the individual level, IPT
use was signiﬁcantly associated with decreased risk of TB in
Kenya, not associated in Tanzania, and associated with
increased risk in Uganda. Paradoxically, at the facility level,
availability of IPT at the HIV clinic was signiﬁcantly
associated with a higher risk of TB in Kenya, whereas the
opposite was true in Uganda. In Tanzania, the variable
dropped out of the model because of collinearity. Finally,
public clinic was associated with lower risk of incident TB in
Kenya, whereas it was associated with higher risk of incident
TB in Uganda.
DISCUSSION
Among 168,330 PLWH receiving HIV care at 35
clinics in Kenya, Tanzania, and Uganda, we found a 5-fold
decline in TB disease incidence from 2007 to 2012 the period
of ART scale-up in which ART coverage among all PLWH
increased from 14% to 46%, 9% to 29%, and 11% to 32%, in
Kenya, Tanzania, and Uganda, respectively.33 The signiﬁcant
declining trend, moreover, was still present after adjustment
for confounding in the multivariate model. The magnitude of
the decline was greater than modeling estimates of HIV-
associated TB incidence.17,18 The WHO Global TB Report of
2014, for example, found a 66%, 110% and 82% decline in
Kenya, Uganda, and Tanzania, respectively, between 2004
and 2013.17 These estimates, however, are for all PLWH
regardless of whether or not they are engaged in HIV care. A
study in a periurban township in South Africa, conversely,
found a 1.7-fold decrease in case of notiﬁcation among
PLWH on ART between 2004 and 2008—a larger decline
than modeling studies.19 Accounting for the shorter observa-
tion period of that study compared with that of this study, the
magnitude of decline observed in our facilities was
still higher.
Findings from this large multicountry study demon-
strate signiﬁcant decreases in annual TB incidence coinciding
FIGURE 1. Trends in crude TB incidence rates
among HIV-positive individuals enrolling in HIV
care in 35 facilities participating in IeDEA East Af-
rica, January 2007–December 2012. Rates for
2003 for Kenya and Uganda and 2006 for Tanza-
nia are not shown due to sparse cells.
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with a decade-long scale-up of ART services, mirroring
studies of single cohorts examining the ART effectiveness
in reducing TB incidence.4–13 We found declining TB
incidence in pre-ART and ART patients. The decline in
pre-ART care could partially be explained by reduced trans-
mission of TB both in the community and in the facility
because of ART scale-up, despite predictions of low effect.34
IPT scale-up among PLWH may also contribute.17 We found
a 33% protective effect of IPT against incident TB. Finally,
the decline may, in part, be an artifact of the very high
incidence of TB among PLWH engaged in care in Kenya in
2004 and Uganda in 2005. These rates may be a function of
either the early effects of HIV epidemic on increased
progression to TB disease in those infected or of active case
ﬁnding in HIV centers or both. A similar phenomenon was
observed in Peru during its initial years of active TB control.35
FIGURE 2. Trends in crude TB incidence rates among HIV-positive individuals enrolling in HIV care in 35 facilities participating in
IeDEA-East Africa, by age group and by ART status, January 2007–December 2012. Rates for patients 18–19 are not shown due to
sparse cells.
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We also found that the SIRs decreased signiﬁcantly,
suggesting that the gap between TB incidence among
PLWH in care and the general population narrowed over
the study period. Despite previous recognition that general
economic development with improved nutrition decreases
TB incidence,36,37 the substantial decline in SIRs suggest
that scale-up of HIV care contributed additional beneﬁt in
reduction of TB disease in PLWH in care as past studies
have shown.19,21 Yuen et al, for example, found estimated
TB incidence rates in Kenya among HIV-negative people
reduced approximately at half the rate of HIV-positive
people (11%–26% vs. 28%–44% decline between 2007 and
2012).21 In our study, despite the greater decline in PLWH
in care, TB incidence among them remained 1.4–4.1 times
higher than in the general population at the end of the study
period in all three countries. This ﬁnding is anticipated;
ART does not return patients, particularly those with a very
low CD4 count to a pre-HIV infection immune status.26,34,38
Consistent with previous studies, use of ART and IPT
was associated with a reduced incidence of TB.4,6–9,13,22,24 As
TABLE 4. Unadjusted and Adjusted Hazard Ratios for Patient and Facility-Level Factors Associated With Incident TB Among
Patients Enrolling in HIV Care in IeDEA East Africa Health Facilities, 2003–2012 (n = 138,394)
HR 95% CI P aHR 95% CI P
Patient-level factors
Age at enrollment 1.004 (1.002 to 1.006) ,0.001 0.996 (0.994 to 0.998) ,0.001
Sex
Male 1.447 (1.394 to 1.504) ,0.001 1.314 (1.263 to 1.368) ,0.001
Female 1.000 1.000
Enrollment year 0.924 (0.916 to 0.933) ,0.001 0.948 (0.938 to 0.958) ,0.001
CD4+ cells/mL at enrolment
0–99 1.000 1.000
100–199 0.824 (0.781 to 0.869) ,0.001 0.911 (0.862 to 0.963) 0.001
200–350 0.806 (0.765 to 0.849) ,0.001 0.981 (0.925 to 1.040) 0.515
351–500 0.662 (0.625 to 0.701) ,0.001 0.837 (0.779 to 0.899) ,0.001
500+ 0.440 (0.411 to 0.471) ,0.001 0.594 (0.547 to 0.645) ,0.001
WHO stage at enrolment
Stage 1 1.000 1.000
Stage 2 1.495 (1.425 to 1.568) ,0.001 1.412 (1.343 to 1.484) ,0.001
Stage 3 2.348 (2.245 to 2.456) ,0.001 2.097 (1.992 to 2.207) ,0.001
Stage 4 2.598 (2.403 to 2.809) ,0.001 2.240 (2.054 to 2.442) ,0.001
Use of ART
Yes 1.168 (1.123 to 1.214) ,0.001 0.843 (0.798 to 0.891) ,0.001
No 1.000 1.000
Use of IPT
Yes 0.716 (0.684 to 0.750) ,0.001 0.767 (0.728 to 0.809) ,0.001
No 1.000 1.000
History of TB* 1.622 (1.504 to 1.750) ,0.001
Facility-level factors
Facility type
Public clinic 1.502 (1.312 to 1.719) ,0.001 1.392 (1.196 to 1.619) ,0.001
Private clinic 1.000 1.000
Population served
Urban 1.000 1.000
Urban and semiurban 0.822 (0.791 to 0.854) ,0.001 0.956 (0.913 to 0.999) 0.049
Rural and semiurban 0.719 (0.663 to 0.780) ,0.001 0.788 (0.723 to 0.859) 0.000
Availability of TB treatment within facility 0.808 (0.778 to 0.839) ,0.001 0.932 (0.878 to 0.989) 0.021
Routine TB screening at the HIV clinic 1.364 (1.119 to 1.663) 0.002 1.260 (1.026 to 1.542) 0.027
Availability of IPT at the HIV clinic 0.889 (0.853 to 0.927) ,0.001 1.042 (0.868 to 1.243) 0.678
Consistency with WHO guidelines for
Cotrimoxazole among PLWH
1.116 (1.071 to 1.162) ,0.001 0.894 (0.781 to 1.024) 0.106
Country
Kenya 1.000 1.000
Tanzania 0.508 (0.458 to 0.564) ,0.001 0.480 (0.407 to 0.565) 0.000
Uganda 1.501 (1.435 to 1.569) ,0.001 1.176 (1.030 to 1.343) 0.016
*Model includes only Kenya and Uganda, as Tanzania did not report this variable.
aHR, adjusted hazard ratio; HR, hazard ratio.
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previously described, female sex,39 higher CD4 cell count,
and lower enrollment WHO stage were associated with lower
hazard of TB.22,23 Although other studies and our unadjusted
models found that increasing age was associated with a higher
hazard of TB,13,24 once we adjusted for immunosuppression
measures at enrollment this ﬁnding was reversed. In post hoc
analyses we found that older PLWH had longer time on ART
than younger PLWH, which may explain this ﬁnding because
longer time on ART has been shown to reduce risk of TB.6
We also found important facility-level factors associated
with incident TB. PLWH receiving care at public-sector
facilities and in facilities serving only urban populations were
more likely to have incident TB. The urban setting has been
linked to higher rates of incident TB in previous studies,
plausibly mediated by high population density and crowded
living conditions.36 PLWH receiving care at health facilities
providing anti-TB treatment onsite were less likely to have
incident TB. Integration of HIV and TB programs has been
associated with high cure and treatment completion rates.40,41
Our study has found that it may also reduce incident TB among
PLWH engaged in care, presumably by reducing TB trans-
mission in the community by reducing treatment delays.
Although IPT was signiﬁcantly associated with reduced risk
of incident TB, availability of IPT at the HIV clinic was not
associated with reduction in incident TB. This may be
explained by availability of IPT not always translating to
patients actually receiving the treatment, a probability in Kenya
where 80% of health facilities reported IPT availability but
only 20% of patients had documentation that they received it.
Our study has some limitations. We had a substantial
amount of missing data, most notably enrollment CD4 cell
count and WHO stage. We used multiple imputation techni-
ques to address CD4 data incompleteness in our analyses.
However, if these data were not missing at random, the results
based on the imputed data could be biased.42
Although the proportion of patients LTFU in our study
was comparable with that of other studies,43–45 attrition bias is
possible if the likelihood of LTFU was associated with
incident TB. Nevertheless, we do not believe that the
signiﬁcant decline in TB incidence found can be explained
by greater LTFU by patients with incident TB, because rates
of LTFU in our study population also declined over the study
period from 58% to 19%.
In addition, we had missing observations resulting in
the models for incident TB using only 82% of the total study
population. However, because demographic and clinical
characteristics of PLWH included in and excluded from the
models were very similar to each other (data not shown), it is
unlikely that model results are seriously biased.
Incident TB was deﬁned as the ﬁrst-documented initia-
tion of anti-TB treatment. Use of anti-TB treatment initiation to
deﬁne incident TB lends itself to misclassiﬁcation biases in
both directions. Diagnostic challenges remain especially in
PLWH where smear negative and extrapulmonary TB are
common; some patients are not diagnosed caused by these
limitations and therefore not treated, whereas other patients are
“overtreated” because of clinician’s fear of missing TB.
SIRs standardized the TB incidence rates of PLWH
engaged in HIV care to the annual TB incidence rates (per
100,000 population per year) for the general population
estimated by the World Health Organization (WHO). Our
study population, however, was PLWH engaged in care
predominantly in public health facilities serving urban
and periurban areas. Because TB incidence is likely higher
in urban areas, SIRs in this study could therefore
be inﬂated.
Another possible limitation relates to the fact that
facility-level factors were assessed in a 2009 survey and
were assumed to be unchanged through the study period. It is
likely that clinic practices for TB treatment within facility,
routine TB screening at HIV clinic, availability of IPT at HIV
clinic, and consistency with WHO guidelines for CPT among
PLWH changed over time so that 2009 practices may not be
representative of earlier or later practices. Such misclassiﬁ-
cations would attenuate associations between health facility
level factors and incident TB.
In addition, it is important to note that although most
health facilities were public health facilities which are the
backbone of the national HIV response in Kenya, Tanzania,
and Uganda, they were not selected to be representative of the
health facilities delivering HIV care in these countries. The
vast majority of the health facilities (77%) and patients (66%)
came from 3 regions in Kenya which represented 7% (38,979/
548,588) of the reported number of adults receiving ART in
Kenya in 2012.46
Finally, there may be important country-level differ-
ences in factors associated with incident TB that we were not
able to fully explore in this analysis. Our sensitivity analyses,
for example, showed that IPT use at individual level was
associated with higher risk of TB in Uganda. We believe,
however, that this is an artifact of poor data quality for that
variable in Uganda (53% missing).
Our study also has important strengths. With data on
nearly 170,000 PLWH with 13,000 incident TB cases from
35 HIV care clinics in three countries with heterogeneous
HIV epidemics, this study during early rapid ART scale-up is
the largest assessment of HIV-related TB incidence in this
region. Six years of observation for the temporal trend
analysis allowed for examination of TB incidence over
a critical period of scale-up of HIV treatment in East Africa.
Using data routinely collected across countries increased the
generalizability of study ﬁndings. Finally, we examined
health facility-level factors associated with TB incidence that
have not been previously examined.
In conclusion, we found a signiﬁcant decline in TB
incidence among patients in HIV care in Kenya, Tanzania,
and Uganda between 2007 and 2012 coincident with the rapid
scale-up of HIV treatment across the region. SIRs signiﬁ-
cantly decreased during in all 3 countries, indicating that the
TB incident rate gap among PLWH in HIV care and that of
the general population narrowed. These ﬁndings are encour-
aging, as efforts continue to improve access to and early
initiation of ART, IPT, and TB/HIV care integration. Future
studies must examine this causal impact of ART scale-up on
reduction of TB incidence and mortality among PLWH.
Minimizing TB remains of critical importance for continued
and sustained success in reduction of morbidity and mortality
in East Africa.
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